drugset / Trial / NCT06388889

Phase III Long-Term Extension Study With Dexpramipexole

NCT06388889

Phase 3 Terminated 509 enrolled Areteia Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial\] is to evaluate the long term safety of dexpramipexole treatment in participants with severe asthma, aged ≥18 years, on Global Initiative for Asthma (GINA) 2021 \[GINA, 2021\] Step 4 or 5 therapy and who completed either of the Phase III studies EXHALE-2 or EXHALE-3.

Timeline

Start
2024-06-12
Primary completion
2025-12-08
Completion
2025-12-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexpramipexole Small molecule 150 mg Oral

Indications